RSV Vaccine Factsheet – Information for Patients, Parents and Carers
Summary
The MHRA published a new patient factsheet on RSV vaccination on 15 April 2026. The factsheet provides comprehensive information about respiratory syncytial virus (RSV), including eligibility criteria, safety and effectiveness of vaccines used in the UK, side effects, pregnancy considerations, and contraindications. The document is designed to help patients, parents, and carers understand RSV vaccines and make informed decisions about vaccination.
What changed
The MHRA published a new patient factsheet providing information on respiratory syncytial virus (RSV) and RSV vaccination in the UK. The factsheet covers RSV overview, vaccination eligibility, co-administration with COVID-19, safety and effectiveness data, side effects, pregnancy considerations, and contraindications.
This factsheet applies to patients, parents, and carers seeking information about RSV vaccination in the UK. Healthcare providers administering RSV vaccines may also use this resource to support patient consultations. The document is informational and does not create new compliance obligations.
What to do next
- Monitor for updates to the factsheet
- Report vaccine side effects to the Yellow Card scheme
- Review eligibility criteria for RSV vaccination
Archived snapshot
Apr 15, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Guidance
RSV Vaccine Factsheet – Information for Patients, Parents and Carers
Patient factsheet providing information on respiratory syncytial virus (RSV) and RSV vaccination.
From: Medicines and Healthcare products Regulatory Agency Published 15 April 2026 Get emails about this page
Documents
RSV Vaccine Factsheet – Information for Patients, Parents and Carers
HTML
Details
Respiratory syncytial virus (RSV) is a common respiratory virus that can cause coughs, colds, and chest infections. While most people who catch RSV experience only mild illness, RSV can sometimes lead to serious illness, such as bronchiolitis and pneumonia, particularly in young babies, older adults, and individuals with weakened immune systems.
RSV infection is one of the most common reasons for young babies to be admitted to hospital. In older adults, RSV can also lead to severe lung infections and breathing difficulties.
Vaccination is one of the safest and most effective ways to protect people who are at higher risk of becoming seriously unwell with RSV. RSV vaccines used in the UK have been rigorously assessed for safety, quality and effectiveness, and are continuously monitored through the Yellow Card scheme.
This factsheet is designed to help patients, parents and carers understand the RSV vaccines used in the UK. It covers:
- Overview of RSV
- RSV vaccination and eligibility
- Getting RSV and COVID-19 vaccination at the same time
- Safety and effectiveness of RSV vaccines
- RSV vaccine side effects
- RSV vaccine and pregnancy
- Who should not receive the RSV vaccine
- Report side effects to the Yellow Card scheme
Updates to this page
Published 15 April 2026
Sign up for emails or print this page
Get emails about this page Print this page
Named provisions
Related changes
Get daily alerts for MHRA Guidance & Safety
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from MHRA.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when MHRA Guidance & Safety publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.